Can Plasma Exchange Really Make You Biologically Younger?

Therapeutic plasma exchange can shift several blood-based biological-age measures in a younger direction in healthy adults over 50. That is a real finding from a placebo-controlled trial—not proof that the procedure makes a healthy person younger in any meaningful clinical sense.

The distinction matters. Aging clocks, proteomic profiles, and other omic measures can capture useful biology. They cannot yet tell you whether an invasive procedure will preserve strength, prevent dementia, reduce disease, or extend life. For elective longevity use, those are the outcomes that count.

A controlled human test, with an important catch

A 2025 single-blinded, randomized, placebo-controlled trial by Fuentealba et al. tested therapeutic plasma exchange (TPE) in healthy adults older than 50. Participants received monthly TPE, TPE every two weeks, TPE every two weeks combined with intravenous immunoglobulin (IVIG), or a sham procedure.

The study measured epigenetic clocks and multi-omic markers associated with biological age. Compared with sham treatment, the active regimens produced younger-looking movement in several of these blood-based readouts. The largest apparent signal occurred in the more frequent TPE-plus-IVIG group.

This design deserves more attention than the usual before-and-after longevity testimonial. A sham comparator helps separate treatment effects from ordinary variation, expectation effects, and changes that happen simply because researchers measured people twice. Still, the trial was small and short, and it evaluated surrogate endpoints rather than health outcomes. The publication does not establish a durable benefit after treatment ends.

TPE has a controlled human biomarker signal. It does not yet have controlled evidence that it rejuvenates healthy people in the ways they can feel, measure, or live longer with.

Why changing plasma might change aging biomarkers

TPE removes plasma and replaces it with a substitute fluid. That can rapidly change the composition of the blood compartment: proteins, antibodies, lipoproteins, inflammatory signals, and molecules involved in coagulation. A 2024 study by Pitkanen et al. found that TPE materially altered intact protein S, apolipoproteins, and thrombin-generation biology. That is direct evidence that the procedure is biologically disruptive enough to change what blood assays detect.

It also offers a less magical explanation for favorable clock movement. If an intervention substantially remodels the sample being measured, a blood-based biomarker can move without proving that every organ has become younger. The change may still matter. It simply needs to earn its clinical interpretation.

The broader rationale has scientific footing. A 2025 review by Sviercovich and colleagues argues that age-related changes in circulating proteins, protein production, and biological noise may help drive aging phenotypes. A 2026 comparative-proteomics study found that plasma inflammatory profiles vary with age, sex, and life experience. Plasma is not inert plumbing; it carries information about inflammation, metabolism, immune activity, and prior exposures.

Experimental work supports that general idea without settling the clinical question. In a human microphysiological co-culture system, Ritter et al. found that young human serum altered responses in skin and bone-marrow-derived blood cells. Skin proliferation improved and methylation-based biological age fell in the model, but only when bone-marrow-derived cells were present. That is interesting human-cell biology, not evidence that exchanging an older adult's plasma restores whole-body function.

The IVIG problem is central

The trial's most favorable regimen paired more frequent TPE with IVIG. That makes it impossible to assign the apparent advantage cleanly to plasma removal.

IVIG has its own immunologic effects. More frequent exchange also creates a different biological exposure than monthly exchange. The observed signal could reflect the exchange schedule, IVIG, their interaction, replacement-related changes, or some mixture of all four. Until a study separates those variables, "plasma exchange caused the strongest rejuvenation" overstates what the trial can show.

This is not a pedantic footnote. The treatment package matters to anyone considering elective use, because IVIG is a blood-derived medical therapy with its own costs, supply constraints, and risks.

Aging clocks are meaningful—but incomplete

The case for taking biological-age measures seriously is stronger than the case for treating them as a verdict on rejuvenation. In 2,656 Hispanic/Latino adults, Fornage et al. reported associations between epigenetic aging measures and plasma biomarkers related to amyloid, tau, neurodegeneration, and neuroinflammation. In cognitively unimpaired older women, Zhang et al. found that baseline epigenetic age acceleration and pace-of-aging measures related to Alzheimer's biomarker patterns, including longitudinal changes over 15 years.

Those studies show that clock outputs can track biology linked to disease risk. They do not show that a short-term intervention-induced clock shift prevents Alzheimer's disease or improves brain health. Association is not treatment evidence.

Different clocks and omic measures also do not necessarily measure one unified thing called "biological age." A 2023 multi-omic analysis by Robinson et al. found that biological-age markers could diverge across domains. A systematic review by Oblak et al. likewise found that epigenetic-clock acceleration relates to many biological, social, and environmental factors. A biomarker can respond to a real physiological change without serving as a complete report card for the entire organism.

Procedure burden changes the standard of proof

TPE is established medicine for specific conditions. That does not make it a low-stakes wellness intervention. It requires specialized clinical delivery and changes hemostatic biology as well as plasma proteins. A 2024 case report described hyperchloremic metabolic acidosis after plasma exchange in a patient treated for renal-transplant rejection. One case report cannot estimate risk in healthy adults, but it illustrates why "it only changes blood" is a poor safety summary.

Cost and resource use also matter. A 2025 analysis by Antelo et al. examined the substantial resource burden of TPE and IVIG in immune-based neurological disease. A biomarker-only benefit has to clear a much higher bar when the intervention is invasive, expensive, and dependent on clinical infrastructure and blood products.

Reviews of young blood, plasma, and blood-based anti-aging approaches describe a legitimate research program, not an established longevity service. Hosseini et al. and Liu et al. summarize hypotheses involving circulating inflammatory, metabolic, and regenerative factors. The unanswered translation question remains the same: can changing the blood milieu produce durable improvements in human healthspan?

Verdict: interesting signal, unproven therapy

The Fuentealba trial makes elective TPE harder to dismiss as pure anti-aging theater. It showed that a sham-controlled intervention can move multiple blood-based aging biomarkers in healthy older adults, especially in a higher-intensity regimen that included IVIG.

But the study did not demonstrate improved physical function, cognition, frailty, disease incidence, survival, or lasting benefit after treatment stopped. Its strongest regimen cannot isolate TPE from IVIG. Larger independent sham-controlled trials need to test whether the biomarker changes replicate and whether they predict outcomes a healthy person would actually value.

For now, therapeutic plasma exchange is an invasive medical experiment with provocative biomarker data—not proven rejuvenation medicine.